Nurix Highlights 83% ORR, 22.1-Month PFS for Bexobrutideg and Phase 2 Launch
Nurix’s ASH2025 update showed bexobrutideg achieved an 83% ORR, 4.3% CR rate and median PFS of 22.1 months in r/r CLL, leading regulators to clear a 600 mg daily dose. The company launched the DAYBreak CLL-201 Phase 2 trial, plans a Phase 3 in 2026, and advances IRAK4 and STAT6 degrader collaborations.
1. Bexobrutideg Demonstrates Superior Clinical Profile
Nurix’s lead BTK degrader candidate achieved an 83% objective response rate in relapsed or refractory chronic lymphocytic leukemia (CLL) patients treated at a median of four prior lines of therapy, including two complete responses (4.3%). Median progression-free survival reached 22.1 months, outpacing currently approved BTK inhibitors in similar patient populations. Across all dose cohorts, no dose-limiting toxicities were observed, underscoring a favorable safety and tolerability profile that supports potential best-in-class differentiation.
2. Strategic Dose Selection and Pivotal Trial Initiation
Following alignment with U.S., U.K. and European regulators under Project Optimus, Nurix selected a 600 mg once-daily dose for pivotal development after observing higher response rates and extended progression-free survival compared with the 200 mg cohort, without incremental adverse events. Enrollment is underway in the DAYBreak CLL-201 Phase 2 single-arm study evaluating 600 mg in CLL patients who progressed on both BTK and BCL-2 inhibitors. A confirmatory Phase 3 trial, DAYBreak CLL-306, is slated to begin in 2026 to support full global registration.
3. Robust Financial Runway and R&D Investments
With a cash position exceeding $650 million at year-end 2025, Nurix expects to fund operations through 2028. This financial strength enables acceleration of internal programs and external partnerships, including co-development of an oral IRAK4 degrader with Gilead and a STAT6 degrader with Sanofi. Capital allocation prioritizes the DEL-AI discovery engine, supporting expansion of degrader modalities across oncology, inflammation and autoimmune indications.
4. 2026 Corporate Objectives and Upcoming Catalysts
In 2026, Nurix aims to: (1) complete enrollment of the Phase 2 DAYBreak CLL-201 study and initiate DAYBreak CLL-306; (2) file an IND for a tablet formulation of bexobrutideg in autoimmune and inflammatory diseases; (3) advance partnered inflammation programs through Phase 1 IRAK4 trials and STAT6 preclinical milestones; and (4) leverage DEL-AI to nominate at least two new protein degrader candidates. These catalysts position Nurix to deliver multiple value-inflection points over the next 12 to 18 months.